Table 1 General information and laboratory results of patients with BALF samples
From: One-step diagnosis of infection and lung cancer using metagenomic sequencing
| Â | Negative Onco-mNGS signals | Positive Onco-mNGS signals | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Infection | Non | Tumor | Tumor with infection | LY | Othera | Lung cancer | |||||
(n = 88) | (n = 22) | (n = 5) | (n = 5) | (n = 2) | (n = 1) | SCLC | MC | NSCLC | |||
|  |  |  |  |  |  | (n = 4) | (n = 3) | SCC | ADC | Others | |
|  |  |  |  |  |  |  |  | (n = 20) | (n = 35) | (n = 5) | |
Age, years, median (min,max) | 55 (17, 83) | 57 (33,78) | 67.5 (48, 76) | 58 (49, 72) | 32 (32,32) | 75 | 67 (58,75) | 50 (44,70) | 67 (53,82) | 60 (27,90) | 72 (41,83) |
Gender, male/female | 47/41 | 15/21 | 1/4 | 5/0 | 2/0 | 1/0 | 4/0 | 1/2 | 19/1 | 17/18 | 3/2 |
Smoking, yes/no/NA | 22/65/1 | 9/26/1 | 1/4/0 | 4/1/0 | 2/0/0 | 1/0/0 | 4/0/0 | 0/3/0 | 15/5/0 | 12/23/0 | 3/2/0 |
Underlying diseases, yes/no/NA | 35/52/1 | 13/22/1 | 4/1/0 | 2/3/0 | 1/1/0 | 1/0/0 | 2/2/0 | 1/2/0 | 13/7/0 | 17/18/0 | 5/0/0 |
Laboratory examinations, median (min, max) | |||||||||||
 WBC (× 109/L) | 6.6 | 6.19 | 5.6 | 6.58 | 4.165 | 5.93 | 7.25 | 5.15 | 8.37 | 6.3 | 5.8 |
(1.88, 22.1) | (2.36, 15.91) | (4.8, 12.05) | (5.74, 16.4) | (3.95,4.38) | (7.04,18.14) | (3.65,9.91) | (4.70,23.74) | (3.81,14.30) | (4.40,9.30) | ||
 Neutrophil (× 109/L) | 4 | 3.5 | 3.2 | 4.2 | 3 | 4.7 | 5.1 | 3.6 | 5.64 | 4 | 5.8 |
(1.1, 18.2) | (1.2, 12.3) | (2.5, 7.4) | (2.7, 14.6) | (2.5,3.5) | (3.20,15.20) | (2.50,71.70) | (2.30,20.60) | (1.40,10.20) | (2.90,7.00) | ||
 CRP (mg/L) | 3.09 | 0.5 | 11.85 | 13.08 | NA | NA | NA | 0.885 | 4.91b | 0.22b | 1.625b |
(0.03, 109.13) | (0.05, 21.86) | (4.84, 18.86) | (0.49, 29.71) | (0.07,1.70) | (0.06,36.52) | (0.03,2.86) | (1.23,2.02) | ||||
 PCT (mg/L) | 0.13 | 0.1 |  < 0.05 | 0.22 | 0.13a | 0.09 | 0.105 |  < 0.05 | 0.19b | 0.13b |  < 0.05b |
(< 0.05, 7.92) | (< 0.05, 0.13) | (< 0.05, < 0.05) | (0.14, 0.25) | (0.06,0.15) | (0.08,0.49) | (0.05,19.47) | (0,0.07) | ||||
Potential diagnostic biomarkers | |||||||||||
 CEA | 2.12 | 2.91 | 4.44 | 1.97 | 0.62a | 2.51 | 2.39 | 2.3 | 4.05 | 4.99 | 4.40b |
(0.31, 8.7) | (0.76, 17.89) | (1.02, 9.59) | (0.45, 3.4) | (1.47,10.70) | (1.51,2.40) | (1.78,27.50) | (0.73,125) | (2.47,4.50) | |||
 NSE | 2.49 | 2.61 | 3.89 | 2.77 | 2.81a | 5.51 | 3.98 | 4.2 | 7.6 | 5.515 | 5.39b |
(0.84, 54.1) | (1.47, 7.4) | (2.58, 15.1) | (2.02, 11.13) | (2.98,4.44) | (2.70,6.23) | (1.83,474) | (1.24,57.50) | (5.25,8.38) | |||
 CA125 | 24.27 | 17.92 | 12.3 | 21 | 18.6a | 20.4 | 10.2 | 30.8 | 25.26 | 23.5 | 73.80b |
(4.73, 1217) | (5.5, 96.2) | (9.52, 30.8) | (12.1, 47.66) | (7.83,73.5) | (28.1,74.5) | (5.57,212) | (3.93,1263) | (13.40,108) | |||
 CA153 | 12.28 | 12.7 | 10.3 | 17.55 | 22.8a | 59.4 | 7.54 | 12.9 | 11.315 | 17.75 | 17.99b |
(3.52, 109) | (5.18, 62.01) | (6.77, 22.5) | (6.34, 24.1) | (5.25,11) | (6.5,14.9) | (4.41,40.40) | (6.99,127) | (5.59,20.50) | |||